Impact of FDA Updates on Public Interest in Breast Implant-associated Anaplastic Large Cell Lymphoma

Mansher Singh, MD*
Gayatri Singh, MD†
Anupam Singh Chauhan, MD‡
Harrison H. Lee, MD, DMD, FACS§
Justin M. Sacks, MD, FACS*
Charles S. Hultman, MD, MBA, FACS*
Mark G. Albert, MD¶

Summary: In the United States, the Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety, efficacy, and security of drugs, biological products, and medical devices. In that role, FDA releases timely updates with regard to medical devices and their possible adverse effects. However, the impact of such FDA updates on public interest has not been studied. The timing of multiple FDA updates regarding Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) was noted from September 2014 to September 2019. Impact on Public interest related to ALCL was measured using Google Trends and the number of YouTube video uploads. These objective markers were used to compare the public interest during FDA updates versus weeks with no FDA updates. Five major updates were released by FDA regarding BIA-ALCL during the past 5 years. Google Trends demonstrated a significant increase in public interest regarding ALCL during the week of FDA release, with a mean score of 69 ± 20.82 when compared with a mean score of 10.68 ± 4.71 (P < 0.001) during weeks with no FDA release. The mean number of YouTube videos uploaded during the period of FDA release was 11.8 ± 9.42, which was significantly higher than the mean of 2.42 ± 1.31 videos (P < 0.001) during the period of no FDA updates. FDA updates correlates with temporal increase in public interest. Plastic surgeons should be aware of FDA information releases on BIA-ALCL and anticipate an increased interest in additional information from patients and the public. (Plast Reconstr Surg Glob Open 2020;8:e3240; doi: 10.1097/GOX.0000000000003240; Published online 24 November 2020.)

INTRODUCTION

In the United States, the Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety, efficacy, and security of biological products and medical devices. FDA releases timely updates with regard to medical devices and their possible adverse effects. Lately, Breast Implant-associated Anaplastic Large cell Lymphoma (BIA-ALCL) has generated significant interest, resulting in multiple FDA updates.1–5

As of September 2019, there have been 573 unique cases of BIA-ALCL reported worldwide, with 33 deaths.6 The number of reported cases has steadily increased since the FDA’s first report on BIA-ALCL in 2011.7–10 BIA-ALCL has been reported in both breast augmentation and post-mastectomy breast reconstruction patients.7–10 BIA-ALCL is closely related to the use of textured breast implants. Biocell implants by Allergan display a 6-fold greater risk for the development of BIA-ALCL, which has resulted in a worldwide recall of this product at the behest of the FDA.6

Although FDA plays a significant regulatory role, the impact of FDA updates on general public interest has not been studied. Using BIA-ALCL as a case in point, we evaluated the impact of FDA updates on public interest.

METHODS

Recent FDA updates regarding BIA-ALCL released were searched online. On September 20, 2019, we used the keyword “Anaplastic Large-Cell Lymphoma” on Google Trends tool (Google.com/trends)11 to obtain a temporal interest plot from September 2014 to September
The search interest represents searches for a specific keyword, relative to the total number of searches done on Google over time. The data are normalized and presented on a scale from 0 to 100. Mean Google Trends score was calculated and compared between the weeks with and without FDA updates.

A search was made on September 20, 2019 in YouTube (www.youtube.com) for videos related to BIA-ALCL from January 2017 to August 2019. This timeline was chosen to capture all the FDA updates. The number of relevant videos was recorded in 2-month blocks. More than 1 upload from the same account during each block was counted as 1 video. The mean number of video uploads was calculated and compared between the periods with and without FDA updates.

GraphPad Prism (v 7.00, La Jolla, Calif.; www.graphpad.com) was used for statistical analysis. \( P < 0.05 \) was considered as statistically significant.

**RESULTS**

Five major FDA updates related to BIA-ALCL over the past 5 years were included in our study (Table 1). The dates for release were March 21, 2017; November 20, 2018; February 6, 2019; March 25–26, 2019; and July 24, 2019. We observed a significant spike in search interest for “Anaplastic Large-Cell Lymphoma” during each of the 5 weeks of FDA updates (Fig. 1). On a scale of 0 to 100, the Google Trends score ranged from 40 to 100 during these 5 weeks. The maximum Google Trends score during the remaining 256 weeks was 30, which was immediately after the week of last FDA release. The mean Google Trends score during the weeks of FDA updates was 69 ± 20.82 versus a mean score of 10.68 ± 4.71 (\( P < 0.001 \)) during the weeks with no FDA updates.

There was a significantly increased number of YouTube video uploads during the period of FDA updates (Fig. 2). The mean number of YouTube video uploads during the period of FDA updates was 11.80 ± 9.42 compared with a
mean of 2.42 ± 1.31 video uploads (P < 0.001) during the period with no FDA updates.

**DISCUSSION**

FDA has played a significant role in regulating the use of breast implants for both reconstructive and cosmetic purposes. In January 1992, FDA issued a voluntary moratorium on silicone-gel–filled breast implants, requesting that manufacturers stop supplying them and surgeons stop implanting them pending further review. In June 1998, FDA approved the use of silicone-gel–filled breast implants for a limited number of augmentations, reconstruction, and revision patients at a limited number of sites based on Allergan’s investigation device exemption study. Silicone-gel–filled breast implants were not approved by FDA for breast augmentation for cosmetic indication till November 2006. In January 2011, FDA issued a safety communication on ALCL in women with breast implants. This was followed by multiple updates (which are included in our study), leading to the latest communication causing worldwide voluntary recall of Natrelle BIOCELL textured Allergan breast implants. While the regulatory role of FDA is well established, the effect of such updates on public interest is largely unknown.

Using multiple internet platforms, we objectively demonstrate a significant surge in public interest, which correlates temporally with FDA updates. The increased public interest has several implications for health care providers. Physicians should stay current with FDA updates because the patients may seek detailed information for improved understanding. The transient but significant spike in public interest provides an invaluable opportunity to reach out to general public and prospective patients about the risk factors, symptoms, and danger signs of BIA-ALCL. Perhaps the FDA should consider the dissemination of information in a more timely and audience-inclusive fashion by using these internet portals more effectively. One of the effective ways to achieve this might be to have a stronger online presence of FDA on internet and social media and reaching out to targeted patient groups. A collaborative effort between FDA and plastic surgeons will also result in improved patient engagement. Just simply releasing an update and allowing news sources to follow it might not be the most effective way of disseminating public health safety information.

Our study has limitations. We excluded search engines such as Yahoo/Bing because Google is the most popular search engine and it captures about 70% of the market share. Our findings are limited to BIA-ALCL and FDA updates and the results should not be extrapolated to other FDA updates.

**Fig. 2. Temporal trend of the number of videos uploaded on YouTube from January 2017-August 2019. The arrows indicate the weeks when there were Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) updates from FDA. The mean number of YouTube video uploads during the period of FDA updates was 11.80 ± 9.42 vs. 2.42 ± 1.31 (P < 0.001) during the period with no FDA updates.**

**REFERENCES**

1. American Society for Aesthetic Plastic Surgery. Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) by the numbers, and what they mean. Available at https://www.surgery.org/sites/default/files/ALCL-member-information_March_24_2017.pdf. Published March 24, 2017. Accessed September 20, 2019.
2. FDA Statement. Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on FDA’s updates to medical device safety action plan to enhance post-market safety. Available at https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-jeff-shuren-md-director-center-devices-and Published November 20, 2018. Accessed September 20, 2019.

3. FDA Statement. Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) – letter to health care providers. Available at https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-letter-health-care-providers Published February 6, 2019. Accessed September 20, 2019.

4. FDA Statement. March 25-26, 2019: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee meeting announcement. Available at https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-25-26-2019-general-and-plastic-surgery-devices-panel-medical-devices-advisory committee Published March 26, 2019. Accessed September 20, 2019.

5. FDA Statement. Questions and answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Available at https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl Published July 24, 2019. Accessed September 20, 2019.

6. FDA Statement. The FDA requests Allergan voluntarily recall Natrelle BIOCELL textured breast implants and tissue expanders from the market to protect patients: FDA safety communication. Available at https://www.fda.gov/medical-devices/safety-communications/fda-requests-allergan-voluntarily-recall-natrelle-biocell-textured-breast-implants-and-tissue Published August 7, 2019. Accessed September 20, 2019.

7. Food and Drug Administration. FDA update on the safety of silicone gel-filled breast implants. Available at https://www.fda.gov/media/80685/download. Published June 18, 2011. Accessed September 20, 2019.

8. Srinivasa DR, Miranda RN, Kaura A, et al. Global adverse event reports of breast implant-associated ALCL: An international review of 40 government authority databases. Plast Reconstr Surg. 2017;139:1029–1039.

9. Jewell M, Spear SL, Largent J, et al. Anaplastic large T-cell lymphoma and breast implants: a review of the literature. Plast Reconstr Surg. 2011;129:651–661.

10. Largent J, Oefelein M, Kaplan HM, et al. Risk of lymphoma in women with breast implants: analysis of clinical studies. Eur J Cancer Prev. 2012;21:274–280.

11. Google.com. Export, embed, and cite Trends data. Available at https://support.google.com/trends/answer/87285?hl=en&ref_topic=13975. Accessed September 21, 2019.